Clinical trial · Interventional
A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma
A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Relapse and Metastasis of Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial is designed to provide one kind of modalities for preventing the recurrence and metastasis of PLC. If the expected therapeutic efficacy is achieved, it shall contribute actively to boosting the therapeutic level of PLC, prolonging its recurrent time and enhancing its overall survival. And it may also raise the clinical recognition of this technology, promote its clinical applications and generate excellent social reputations and economic returns.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Drug Use | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Licartin and CIK | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Licartin，Licartin and CIK
- description
- Intravenous Licartin 27.75 M Bq(0.75 mCi)/kg Licartin and CIK
- interventionNames
- Biological: Licartin and CIK
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Definite pathological diagnosis of hepatocellular carcinoma * Excellent healing of surgical wounds, no overt surgical complication and stable disease * Such imaging examinations as ultrasound, CT and MRI reveal no definite tumor foci * Subject's physical status:Karnofsky performance status score ≥70 points * Metuxitab skin test negative * Receiving no radiotherapy, chemotherapy or molecular targeted therapy within 4 weeks pre-therapy * Male/female aged 18-70 years * Expected survival period \> 3 months * Voluntary group participation, excellent compliance, cooperative in observations and signing a written informed consent form. Exclusion Criteria: * Poor general constitution with obviously impaired liver function (bilirubin \> 3 folds of normal upper limit and serum albumin \<30 g/L) * Blood routine examination: white blood cell \<4.0×109/L or platelet count \<80×109/L * Definite tumor foci found on such imaging examinations of ultrasound, CT or MRI * Postoperative onset of recurrence or metastasis and no clinical remission after therapy * Severe infection, such as hepatic abscess * Abnormal thyroid functions * Obvious cases of pleural effusion and ascites * Diffuse systemic metastasis and therapy is not expected to prolong the patient's survival period * Poor compliance * Patients with a history of hypersensitivity to biological preparations, hypersensitive physique or currently in a hypersensitive state * Pregnant and lactating women
References
Publications (0)
Data not yet available